KU-596

has neuroprotective activity; structure in first source

Also Known As:

N-(2-(5-((3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3'-fluoro(1,1'-biphenyl)-2-yl)ethyl)acetamide

Networked: 4 relevant articles (1 outcomes, 2 trials/studies)

1.	Blagg, Brian S J: 4 articles (01/2019 - 08/2014)
2.	Dobrowsky, Rick T: 2 articles (01/2019 - 01/2018)
3.	Zhang, Zheng: 2 articles (01/2019 - 01/2018)
4.	You, Zhenyuan: 1 article (01/2019)
5.	Fowler, Stephen C: 1 article (01/2018)
6.	Li, Chengyuan: 1 article (01/2018)
7.	Zhang, Xinyue: 1 article (01/2018)
8.	Forsberg, Leah K: 1 article (01/2017)
9.	Holzbeierlein, Jeffrey: 1 article (01/2017)
10.	Liu, Weiya: 1 article (01/2017)

1.	Demyelinating Diseases (Demyelinating Disease) 01/01/2018 - "KU-596 therapy did not interfere with MAPK activation but reduced c-jun expression, significantly improved motor performance, and ameliorated the extent of peripheral nerve demyelination in both prevention and intervention studies. "
2.	Neurodegenerative Diseases (Neurodegenerative Disease) 08/01/2014 - "Structure-activity relationship studies on novobiocin and novobiocin analogues, led to the development of KU-32 and recently, KU-596, as lead compounds for the potential treatment of neurodegenerative diseases. "
3.	Neoplasms (Cancer) 01/01/2017 - "Neuroprotective Hsp90 C-terminal inhibitors (novologues) contain a biaryl ring system, and include KU-596, which was modified and investigated for potential anti-cancer activity. "
4.	Hyperglycemia 01/01/2019 - "Downregulating MnSOD in diabetic WT neurons increased hyperglycemia-induced superoxide levels, which was still significantly decreased by KU-596. " 01/01/2019 - "In diabetic WT and Hsp70 KO neurons, hyperglycemia significantly increased superoxide levels, but KU-596 only decreased superoxide in WT neurons. "

1.	Therapeutics